Accessibility Menu
Embecta logo

Embecta(NASDAQ) EMBC

Market Cap$211.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-91%
5 YearN/A
1 Year-63%
1 Month+9%
$3.57
-0.14%
-0.00Today
Embecta last closing stock price
MetricPriceDate
Last closeUSD 3.572026-08-05
Embecta stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.99%USD 3.682026-07-29
1 month+8.84%USD 3.282026-07-06
3 month-0.53%USD 3.592026-05-07
Year to date-69.42%USD 11.672025-12-31
1 year-62.51%USD 9.522025-08-05
3 year-81.17%USD 18.962023-08-04
Since inception-91.24%USD 40.742022-03-22

Embecta Financials at a Glance

Market Cap

$211.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.04B

Net Income (TTM)

$111.90M

EPS (TTM)

$1.90

P/E Ratio

1.88

Dividend

$0.46

Beta (Volatility)

0.00 (Low)

Price

$3.57

Volume

518,555.073

Open

$3.52

Previous Close

$3.57

Daily Range

$3.50 - $3.62

52-Week Range

$2.77 - $15.55

Estimated Earnings Date

Aug 7, 2026

EMBC News

Diabetes woman with pen syringe

Why Embecta Stock Is Tanking Today

Keith SpeightsFeb 9, 2024
novartisandmeridian

3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential

James HalleyMar 26, 2023
Person using blood sugar monitoring system

Why Embecta Stock Popped by Nearly 13% Today

Eric VolkmanFeb 14, 2023
Diabetes type 1

Why Embecta Stock Is Sinking Today

Keith SpeightsDec 20, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Embecta

Embecta makes tools for people living with diabetes. Its products help users inject insulin safely every day. The company sells syringes and needles to patients and clinics.

The Diabetes Care Portfolio

  • Pen Needles: Sterile, single-use medical devices used with pen injectors; accounted for 71% of revenue in Q1 2026.
  • Syringes: Sterile tools used to deliver insulin doses drawn from traditional vials.
  • Safety Devices: Needles and syringes equipped with protective shields to prevent accidental skin punctures.
  • Contract Manufacturing: Production services for non-diabetes medical items sold to BD.

Refining the Strategic Path

  • Spun off from Becton, Dickinson and Company (BD) in April 2022 to become an independent entity.
  • Discontinued the insulin patch pump development program in November 2024 to focus resources on core products.
  • Sold patch pump intellectual property and long-lived assets in Q1 2026 for $10.1 million.
  • Launched the 2025 Restructuring Plan to streamline the organization and optimize business resources.

Global Scale and Heritage

Embecta manages a manufacturing and supply chain footprint rooted in a century of industry history. Its distribution network supports approximately 30 million users across more than 100 countries.

Revenue and Profit Trends

  • Revenue was $261.2 million in Q1 2026, down 0.3% from the previous year.
  • Gross profit rose to $161.7 million in Q1 2026, up 2.9% year-over-year.
  • Operating income reached $83.3 million in Q1 2026, up 190.2% from the prior year period.
  • Net income hit $44.1 million in Q1 2026, up from $0 in the previous year.
  • Free cash flow hit $16.6 million in Q1 2026.

Company Evolution

Embecta has transitioned from a corporate division into a specialized, independent provider of diabetes injection tools. The firm is currently streamlining operations by exiting experimental programs to prioritize its established high-volume injection portfolio.

AI Generated • May 5, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1,850

CEO

Devdatt Kurdikar, PhD, MBA

Website

www.embecta.com

Headquarters

Parsippany, NJ 07054, US

EMBC Financials

Key Financial Metrics (TTM)

Gross Margin

62.52%

Operating Margin

29.78%

Net Income Margin

10.73%

Return on Equity

-17.48%

Return on Capital

42.27%

Return on Assets

10.87%

Earnings Yield

53.19%

Dividend Yield

12.89%

Payout Ratio

31.55%

Stock Overview

Market Cap

$211.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.33M

Volume

518.56K

Avg. Volume

2.31M

Financials (TTM)

Gross Profit

$651.80M

Operating Income

$310.50M

EBITDA

$322.20M

Operating Cash Flow

$213.50M

Capital Expenditure

-$8.80M

Free Cash Flow

$204.70M

Cash & ST Invst.

$184.90M

Total Debt

$1.36B

Embecta Performance Analysis

Embecta annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 1,129,500,000-3.0%
20232023-09-30USD 1,120,800,000-0.8%
20242024-09-30USD 1,123,100,0000.2%
20252025-09-30USD 1,080,400,000-3.8%
Embecta sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-3014.1%
Q42025-09-30-10.7%
Q12025-12-31-1.1%
Q22026-03-31-15.1%
Embecta annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD 3.92-46.4%
20232023-09-30USD 1.22-68.9%
20242024-09-30USD 1.3410.1%
20252025-09-30USD 1.6220.6%
Embecta sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-3095.0%
Q42025-09-30-42.3%
Q12025-12-3164.4%
Q22026-03-31-109.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$221.80M

-14.4%

Gross Profit

$125.20M

-22.5%

Gross Margin

56.45%

N/A

Market Cap

$211.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$114.49K

N/A

Employees

1,850

N/A

Net Income

-$4.10M

-117.4%

EBITDA

$44.90M

-39.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$184.90M

-11.7%

Total Debt

$1.36B

-12.5%

Accounts Receivable

$147.10M

-27.4%

Inventory

$192.60M

+13.8%

Long Term Debt

$1.34B

-12.6%

Short Term Debt

$13.00M

+0.8%

Return on Assets

10.87%

N/A

Return on Invested Capital

39.71%

N/A

Free Cash Flow

$30.60M

-3.5%

Operating Cash Flow

$31.10M

-2.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SIGASIGA Technologies, Inc.
$3.12-0.90%
EBSEmergent BioSolutions Inc.
$5.13-32.03%
MYGNMyriad Genetics, Inc.
$3.09-1.90%
EVHEvolent Health, Inc.
$3.67+18.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$110.08+0.02%
NVDANvidia
$220.55+0.01%
SOUNSoundHound AI
$7.07+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.64-0.02%

Questions About EMBC

What is the current price of Embecta?

Embecta is trading at $3.56 per share.

What is the 52-week range for Embecta?

Over the past 52 weeks, Embecta has traded between $2.77 and $15.55.

How much debt does Embecta have?

As of the most recent reporting period, Embecta reported total debt of $1.37B.

How much cash does Embecta have on hand?

Embecta reported $193.40M in cash and cash equivalents in its most recent financial results.

What is Embecta’s dividend yield?

Embecta currently has a dividend yield of 12.89%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services